Establishment of the surrogate marker of cancer immunotherapy and the study of hyperthermia as the method of increased efficacy

• Project/Area Number: 24890196
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Single-year Grants
• Research Field: General internal medicine (including Psychosomatic medicine)
• Research Institution: Kyoto Prefectural University of Medicine
• Principal Investigator: OKAYAMA Tetsuya 京都府立医科大学, 医学(系)研究科(研究院), 助教 (30636535)
• Project Period (FY): 2012-08-31 – 2014-03-31
• Project Status: Completed (Fiscal Year 2013)
• Budget Amount: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000); Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
• Keywords: 癌免疫療法 / サロゲートマーカー / ＩＦＮｇ / 癌 / 免疫治療 / 免疫療法

Research Abstract

We investigated IFNg production in the peripheral whole blood as surrogate marker for cancer immunotherapy. We investigated IFNg production by stimulating with PHA in tumor-bearing mice that was subjected to immunotherapy. IFNg production was increased in treatment group, but the increase of IFNg production was slight, so it was required to consider alternative methods.
Next, we stimulated the peripheral whole blood with ConA, IFNg production increased in proportion to the concentration and stimulation time, but because detected production concentration was low, we examined increasing ConA concentrations. The result was IFNg produciton increased slightly, but we thought it was difficult to use this method as a marker. Then we examined mRNA in IFNg, in 24 hours stimulation, mRNA in IFNg was increased predominantly, so we have established a measurement technique.
At first, we planned to be cultured immune cells and treated with immune cells, these studies was decided to do next.